Strategies for extended serum half-life of protein therapeutics.

With a growing number of protein therapeutics being developed, many of them exhibiting a short plasma half-life, half-life extension strategies find increasing attention by the biotech and pharmaceutical industry. Extension of the half-life can help to reduce the number of applications and to lower doses, thus are beneficial for therapeutic but also economic reasons. Here, a comprehensive overview of currently developed half-life extension strategies is provided including those aiming at increasing the hydrodynamic volume of a protein drug but also those implementing recycling processes mediated by the neonatal Fc receptor.

[1]  J. Bading,et al.  Biodistribution and tumor imaging of an anti-CEA single-chain antibody-albumin fusion protein. , 2008, Nuclear medicine and biology.

[2]  B. Bacon,et al.  Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1. , 2010, Gastroenterology.

[3]  S. Schulte,et al.  Half-life extension through albumin fusion technologies. , 2009, Thrombosis research.

[4]  Lucy J. Holt,et al.  Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs. , 2008, Protein engineering, design & selection : PEDS.

[5]  Tetsu Kobayashi,et al.  Importance of Neonatal FcR in Regulating the Serum Half-Life of Therapeutic Proteins Containing the Fc Domain of Human IgG1: A Comparative Study of the Affinity of Monoclonal Antibodies and Fc-Fusion Proteins to Human Neonatal FcR , 2010, The Journal of Immunology.

[6]  Kirstin A. Zettlitz,et al.  The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein. , 2010, Protein engineering, design & selection : PEDS.

[7]  Charles L Brooks,et al.  Albumin binding to FcRn: distinct from the FcRn-IgG interaction. , 2006, Biochemistry.

[8]  Yik Andy Yeung,et al.  A therapeutic anti-VEGF antibody with increased potency independent of pharmacokinetic half-life. , 2010, Cancer research.

[9]  Felix Kratz,et al.  Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[10]  Simona Jevševar,et al.  PEGylation of therapeutic proteins , 2010, Biotechnology journal.

[11]  R. Kontermann,et al.  Bispecific Antibodies for Cancer Immunotherapy , 2010, BioDrugs.

[12]  R. Kontermann,et al.  N-Glycosylation as Novel Strategy to Improve Pharmacokinetic Properties of Bispecific Single-chain Diabodies* , 2008, Journal of Biological Chemistry.

[13]  Jos H. Beijnen,et al.  Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies , 2010, Clinical pharmacokinetics.

[14]  R. Kontermann,et al.  Improved Pharmacokinetics of Recombinant Bispecific Antibody Molecules by Fusion to Human Serum Albumin* , 2007, Journal of Biological Chemistry.

[15]  J. Sturis,et al.  Insulin detemir is a fully efficacious, low affinity agonist at the insulin receptor , 2010, Diabetes, obesity & metabolism.

[16]  Leslie R Evans,et al.  The production, characterisation and enhanced pharmacokinetics of scFv-albumin fusions expressed in Saccharomyces cerevisiae. , 2010, Protein expression and purification.

[17]  M. Otagiri,et al.  Pharmaceutical Strategies Utilizing Recombinant Human Serum Albumin , 2002, Pharmaceutical Research.

[18]  V. Gaberc-Porekar,et al.  Obstacles and pitfalls in the PEGylation of therapeutic proteins. , 2008, Current opinion in drug discovery & development.

[19]  F. Salazar,et al.  Tuning the serum persistence of human serum albumin domain III:diabody fusion proteins. , 2010, Protein engineering, design & selection : PEDS.

[20]  G. Gregoriadis,et al.  Development and Testing of Solid Dose Formulations Containing Polysialic Acid Insulin Conjugate: Next Generation of Long-Acting Insulin , 2010, Journal of diabetes science and technology.

[21]  Christof Baltes,et al.  A portable albumin binder from a DNA-encoded chemical library. , 2008, Angewandte Chemie.

[22]  G. A. Lazar,et al.  Enhanced antibody half-life improves in vivo activity , 2010, Nature Biotechnology.

[23]  R. J. Solá,et al.  Glycosylation of Therapeutic Proteins , 2010, BioDrugs.

[24]  D. Lauffenburger,et al.  Rational cytokine design for increased lifetime and enhanced potency using pH-activated “histidine switching” , 2002, Nature Biotechnology.

[25]  G. Gregoriadis,et al.  Improving the therapeutic efficacy of peptides and proteins: a role for polysialic acids. , 2005, International journal of pharmaceutics.

[26]  Eetu Mäkelä,et al.  Nephrin strands contribute to a porous slit diaphragm scaffold as revealed by electron tomography. , 2004, The Journal of clinical investigation.

[27]  V. Rustgi Albinterferon alfa-2b, a novel fusion protein of human albumin and human interferon alfa-2b, for chronic hepatitis C , 2009, Current medical research and opinion.

[28]  Chichi Huang,et al.  Receptor-Fc fusion therapeutics, traps, and MIMETIBODY technology. , 2009, Current opinion in biotechnology.

[29]  F. Fares,et al.  Development of a long-acting erythropoietin by fusing the carboxyl-terminal peptide of human chorionic gonadotropin beta-subunit to the coding sequence of human erythropoietin. , 2007, Endocrinology.

[30]  R. Kontermann,et al.  Biodistribution of a Bispecific Single-chain Diabody and Its Half-life Extended Derivatives* , 2009, The Journal of Biological Chemistry.

[31]  F. Veronese,et al.  The Impact of PEGylation on Biological Therapies , 2012, BioDrugs.

[32]  B. Haraldsson,et al.  Why do we not all have proteinuria? An update of our current understanding of the glomerular barrier. , 2004, News in physiological sciences : an international journal of physiology produced jointly by the International Union of Physiological Sciences and the American Physiological Society.

[33]  C Simone Fishburn,et al.  The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics. , 2008, Journal of pharmaceutical sciences.

[34]  S. Akilesh,et al.  FcRn: the neonatal Fc receptor comes of age , 2007, Nature Reviews Immunology.

[35]  T. Weimer,et al.  Genetic fusion to albumin improves the pharmacokinetic properties of factor IX , 2009, Thrombosis and Haemostasis.

[36]  Willem P C Stemmer,et al.  A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner , 2009, Nature Biotechnology.

[37]  C. R. Leemans,et al.  Improved tumor targeting of anti–epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology , 2008, Molecular Cancer Therapeutics.

[38]  R. Kontermann,et al.  A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain from streptococcal protein G. , 2007, Protein engineering, design & selection : PEDS.

[39]  R. Kontermann Strategies to Extend Plasma Half-Lives of Recombinant Antibodies , 2012, BioDrugs.

[40]  A. Velázquez,et al.  Starch and albumin mixture as replacement fluid in therapeutic plasma exchange is safe and effective , 2008, Journal of clinical apheresis.

[41]  A. Bar-Ilan,et al.  Designing a long-acting human growth hormone (hGH) by fusing the carboxyl-terminal peptide of human chorionic gonadotropin beta-subunit to the coding sequence of hGH. , 2010, Endocrinology.

[42]  Alessandra Villa,et al.  New strategy for the extension of the serum half-life of antibody fragments. , 2009, Bioconjugate chemistry.

[43]  Bert J Lao,et al.  Improving Therapeutic Properties of Protein Drugs through Alteration of Intracellular Trafficking Pathways , 2008, Biotechnology progress.

[44]  M. Scholle,et al.  Gcg-XTEN: An Improved Glucagon Capable of Preventing Hypoglycemia without Increasing Baseline Blood Glucose , 2010, PloS one.

[45]  V. Tesar,et al.  Discovery and basic pharmacology of erythropoiesis-stimulating agents (ESAs), including the hyperglycosylated ESA, darbepoetin alfa: an update of the rationale and clinical impact , 2010, European Journal of Clinical Pharmacology.

[46]  Lucy J. Holt,et al.  Anti-serum albumin domain antibodies in the development of highly potent, efficacious and long-acting interferon. , 2010, Protein engineering, design & selection : PEDS.

[47]  Kunihiro Hattori,et al.  Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization , 2010, Nature Biotechnology.

[48]  B. Liu,et al.  An Albumin-Conjugated Peptide Exhibits Potent Anti-HIV Activity and Long In Vivo Half-Life , 2009, Antimicrobial Agents and Chemotherapy.

[49]  Gary Walsh,et al.  Biopharmaceutical benchmarks 2010 , 2010, Nature Biotechnology.

[50]  K. Chester,et al.  Site-specific polysialylation of an antitumor single-chain Fv fragment. , 2009, Bioconjugate chemistry.

[51]  K. Tryggvason,et al.  How does the kidney filter plasma? , 2005, Physiology.

[52]  A. Verkleij,et al.  Efficient inhibition of EGFR signalling and of tumour growth by antagonistic anti-EGFR Nanobodies , 2007, Cancer Immunology, Immunotherapy.

[53]  J. Andersen,et al.  Extending Half-life by Indirect Targeting of the Neonatal Fc Receptor (FcRn) Using a Minimal Albumin Binding Domain* , 2010, The Journal of Biological Chemistry.

[54]  Marina Etcheverrigaray,et al.  Highly glycosylated human alpha interferon: An insight into a new therapeutic candidate. , 2010, Journal of biotechnology.

[55]  Mire Zloh,et al.  Disulfide bridge based PEGylation of proteins. , 2008, Advanced drug delivery reviews.

[56]  M. Tabrizi,et al.  Elimination mechanisms of therapeutic monoclonal antibodies. , 2006, Drug discovery today.

[57]  B. Meibohm,et al.  Pharmacokinetic aspects of biotechnology products. , 2004, Journal of pharmaceutical sciences.